Japan's Astellas to Buy U.S. Drugmaker OSI for $4 Bil.
By wchung | 21 Apr, 2026
Astellas Pharma Inc., Japan’s No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide.
Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month.
The acquisition is part of Astellas’ drive to expand its cancer drug business worldwide. OSI’s drugs include Tarceva, for lung cancer, which generated $1.2 billion in global sales last year.
The Japanese maker said it hopes to jointly develop cancer drugs with OSI.
Apart from cancer, OSI focuses on oncology, diabetes and obesity treatments.
TOKYO (AP)
Recent Articles
- Trump Extends Ceasefire Unilaterally
- Anterior to the Heart
- Meta to Capture Employee Mouse Movements, Keystrokes for AI Training
- Judge Blocks Trump Policies Stymying Solar, Wind Projects
- Thousands of Companies File Refund Claims As Tariff Refund System Opens
- Volkswagen to Cut Another 1 Million from Annual Capacity
- China's Changan Aims to Join World's top-10 Carmakers by 2030
- Great Wall Motor to Launch 10 New Cars for European Comeback
- Taiwan Exports Orders Surge to Fastest Pace in Over 16 Years
- Many Americans Question Trump’s Temperament